Is ACOR or XYLD a better dividend investment in 2026?

ACOR currently yields 302.57% with a 5% 5-year dividend growth rate. XYLD yields 11.20% with 0.5% growth. The better choice depends on your goal: ACOR offers higher current income.

What is the dividend yield difference between ACOR and XYLD?

ACOR has a forward dividend yield of 302.57% ($2.00/share annually). XYLD yields 11.20% ($4.30/share annually). The yield gap is 291.37 percentage points.

Home › Compare › ACOR vs XYLD

ACOR vs XYLD: Dividend Comparison 2026

ACOR yields 302.57% · XYLD yields 11.20%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ACOR wins by $107.6K in total portfolio value

INVESTMENT

TIME HORIZON10 years

ACOR

● Live price

302.57%

Share price

$0.66

Annual div

$2.00

5Y div CAGR

-50%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$133.5K

Annual income

$200.19

Full ACOR calculator →

XYLD

Global X S&P 500 Covered Call ETF

● Live price

11.20%

Share price

$38.36

Annual div

$4.30

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.9K

Annual income

$3,351.03

Full XYLD calculator →

Portfolio growth — ACOR vs XYLD

📍 ACOR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ACOR	XYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ACOR + XYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ACOR pays

XYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACOR

Annual income on $10K today (after 15% tax)

$25,718.61/yr

After 10yr DRIP, annual income (after tax)

$170.16/yr

XYLD

Annual income on $10K today (after 15% tax)

$952.37/yr

After 10yr DRIP, annual income (after tax)

$2,848.38/yr

At 15% tax rate, XYLD beats the other by $2,678.21/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACOR + XYLD for your $10,000?

ACOR: 50%XYLD: 50%

100% XYLD50/50100% ACOR

Portfolio after 10yr

$79.7K

Annual income

$1,775.60/yr

Blended yield

2.23%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ACOR right now

ACOR

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Altman Z

-32.7

Piotroski

3/9

XYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACOR buys

XYLD buys

No recent congressional trades found for ACOR or XYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricACORXYLD

Forward yield	302.57% ✓	11.20%
Annual dividend / share	$2.00	$4.30 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	-50%	0% ✓
Portfolio after 10y	$133.5K ✓	$25.9K
Annual income after 10y	$200.19	$3,351.03 ✓
Total dividends collected	$70.1K ✓	$20.2K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: ACOR vs XYLD ($10,000, DRIP)

Year	ACOR Portfolio	ACOR Income/yr	XYLD Portfolio	XYLD Income/yr	Gap
1← crossover	$25,829	$15,128.59	$10,840	$1,120.44	+$15.0K → ACOR
2	$45,896	$18,259.36	$11,786	$1,249.59	+$34.1K → ACOR
3	$64,270	$15,161.61	$12,854	$1,397.78	+$51.4K → ACOR
4	$78,690	$9,921.27	$14,063	$1,568.33	+$64.6K → ACOR
5	$89,875	$5,676.30	$15,434	$1,765.19	+$74.4K → ACOR
6	$99,196	$3,029.49	$16,995	$1,993.14	+$82.2K → ACOR
7	$107,702	$1,562.46	$18,777	$2,257.95	+$88.9K → ACOR
8	$116,034	$792.73	$20,818	$2,566.58	+$95.2K → ACOR
9	$124,555	$399.09	$23,163	$2,927.50	+$101.4K → ACOR
10	$133,474	$200.19	$25,865	$3,351.03	+$107.6K → ACOR

ACOR vs XYLD: Complete Analysis 2026

ACOR — Stock

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Full ACOR Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →

📬

Get this ACOR vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACOR vs SCHD ACOR vs JEPI ACOR vs O ACOR vs KO ACOR vs MAIN ACOR vs QYLD ACOR vs JEPQ ACOR vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.